Clinical trial · Observational
Effect of the PIPAC on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin
Effect of Pressurised Intraperitoneal Aerosol Chemotherapy on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pressurised intraperitoneal aerosol chemotherapy is a new surgical technique, developed for the treatment of initially unresectable peritoneal carcinomatosis. The objective of this study was to compare the results of PIPAC associated with systemic chemotherapy with those of systemic chemotherapy alone in patients with gastric peritoneal carcinomatosis without metastasis other than peritoneal, and WHO performance status \<3.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinomatosis, Peritoneal | Peritoneal Carcinomatosis | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PIPAC with systemic chemotherapy | Drug | — | UNRESOLVED |
| Systemic chemotherapy alone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- PIPAC CHEM
- description
- PIPAC associated with systemic chemotherapy
- interventionNames
- Drug: PIPAC with systemic chemotherapy
- label
- ONLY CHEM
- description
- systemic chemotherapy alone
- interventionNames
- Drug: Systemic chemotherapy alone
Primary outcomes (1)
- measure
- Overall survival at 6 months
- timeFrame
- 6 months
- description
- Overall survival at 6 months from diagnosis of carcinomatosis
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 18 years or over * Patients with adenocarcinoma-type gastric non-resectable péritonéale carcinomatosis. * Patients without metastasis other than peritoneal. * WHO performance status \<3 * Patients treated either with PIPAC administered in alternation with systemic chemotherapy (PIPAC\_CHEM) or by systemic chemotherapy alone (ONLY\_CHEM) * Patient informed Exclusion Criteria: \- Patients opposed
References
Publications (0)
Data not yet available